Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

(2021) Nicole Doria-Rose et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

(2021) Shipo Wu et al.   LANCET INFECTIOUS DISEASES

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

(2021) Michela Antonelli et al.   LANCET INFECTIOUS DISEASES

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

(2021) Zijun Wang et al.   NATURE

A ‘mix and match’ approach to SARS-CoV-2 vaccination

(2021) Meagan E. Deming et al.   NATURE MEDICINE

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

(2021) Tina Schmidt et al.   NATURE MEDICINE

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

(2021) Talia Kustin et al.   NATURE MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

(2021) Emanuele Andreano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine

(2021) Yunlong Cao et al.   CELL RESEARCH

Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2

(2021) Shaojun Zhang et al.   CELL RESEARCH

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination

(2021) Bruno Pozzetto et al.   NATURE

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells

(2017) Qingqing Chen et al.   Human Vaccines & Immunotherapeutics